Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Eosinophilia in Hematologic Disorders.

Literature DB >> 26209894

Eosinophilia in Hematologic Disorders.

Abstract

Eosinophilia in the peripheral blood can be the manifestation various medical conditions, including benign or malignant disorders. There are 3 main types of eosinophilia-associated myeloid neoplasms (MN-eos): myeloid and lymphoid neoplasms, chronic eosinophilic leukemia not otherwise specified, and idiopathic hypereosinophilic syndrome (HES). Imatinib mesylate has revolutionized the treatment of molecularly defined MN-eos, and novel agents have been successfully used to treat HES. The discovery of new, recurrent molecular alterations in patients with MN-eos may improve their diagnosis and therapy. This review focuses on the hematologist's approach to a patient with eosinophilia and treatment options for those with eosinophilic myeloid neoplasms.

Entities: CellLine Chemical Disease Gene Mutation Species

Keywords: Chronic eosinophilic leukemia; Eosinophilia; Hypereosinophilic syndrome; Imatinib; PDGFRA; PDGFRB

Mesh：

Substances：

Year: 2015 PMID： 26209894 PMCID： PMC4515577 DOI： 10.1016/j.iac.2015.04.004

Source DB: PubMed Journal: Immunol Allergy Clin North Am ISSN： 0889-8561 Impact factor: 3.479

61 in total

1. Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.

Authors: E Lierman; S Smits; J Cools; B Dewaele; M Debiec-Rychter; P Vandenberghe
Journal: Leukemia Date: 2012-01-17 Impact factor: 11.528

Review 2. Hyper-IgE syndrome update.

Authors: Kathryn J Sowerwine; Steven M Holland; Alexandra F Freeman
Journal: Ann N Y Acad Sci Date: 2012-01-23 Impact factor: 5.691

Review 3. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis.

Authors: J H Butterfield
Journal: Acta Haematol Date: 2005 Impact factor: 2.195

4. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate.

Authors: J L Schaller; G A Burkland
Journal: MedGenMed Date: 2001-09-07

5. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome.

Authors: S Xiao; S R Nalabolu; J C Aster; J Ma; L Abruzzo; E S Jaffe; R Stone; S M Weissman; T J Hudson; J A Fletcher
Journal: Nat Genet Date: 1998-01 Impact factor: 38.330

6. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.

Authors: Georgia Metzgeroth; Christoph Walz; Philipp Erben; Helena Popp; Annette Schmitt-Graeff; Claudia Haferlach; Alice Fabarius; Susanne Schnittger; David Grimwade; Nicholas C P Cross; Rüdiger Hehlmann; Andreas Hochhaus; Andreas Reiter
Journal: Br J Haematol Date: 2008-10-17 Impact factor: 6.998

7. Treatment of patients with the hypereosinophilic syndrome with mepolizumab.

Authors: Marc E Rothenberg; Amy D Klion; Florence E Roufosse; Jean Emmanuel Kahn; Peter F Weller; Hans-Uwe Simon; Lawrence B Schwartz; Lanny J Rosenwasser; Johannes Ring; Elaine F Griffin; Ann E Haig; Paul I H Frewer; Jacqueline M Parkin; Gerald J Gleich
Journal: N Engl J Med Date: 2008-03-16 Impact factor: 91.245

8. Diversity of clinical manifestations and response to corticosteroids for idiopathic hypereosinophilic syndrome: retrospective study in 33 patients.

Authors: Grzegorz Helbig; Katarzyna Wiśniewska-Piąty; Tomasz Francuz; Joanna Dziaczkowska-Suszek; Sławomira Kyrcz-Krzemień
Journal: Leuk Lymphoma Date: 2012-10-05

9. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.

Authors: Michele Baccarani; Daniela Cilloni; Michela Rondoni; Emanuela Ottaviani; Francesca Messa; Serena Merante; Mario Tiribelli; Francesco Buccisano; Nicoletta Testoni; Enrico Gottardi; Antonio de Vivo; Emilia Giugliano; Ilaria Iacobucci; Stefania Paolini; Simona Soverini; Gianantonio Rosti; Francesca Rancati; Cinzia Astolfi; Fabrizio Pane; Giuseppe Saglio; Giovanni Martinelli
Journal: Haematologica Date: 2007-08-01 Impact factor: 9.941

10. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia.

Authors: Srdan Verstovsek; Ayalew Tefferi; Hagop Kantarjian; Taghi Manshouri; Raja Luthra; Animesh Pardanani; Alfonso Quintás-Cardama; Farhad Ravandi; Pat Ault; Carlos Bueso-Ramos; Jorge E Cortes
Journal: Clin Cancer Res Date: 2009-01-01 Impact factor: 12.531

7 in total

1. Identification of autofluorescent cells in human angioimmunoblastic T-cell lymphoma.

Authors: Igor Buchwalow; Dmitri Atiakshin; Vera Samoilova; Werner Boecker; Markus Tiemann
Journal: Histochem Cell Biol Date: 2017-12-02 Impact factor: 4.304

2. Gene therapy in a murine model of chronic eosinophilic leukemia-not otherwise specified (CEL-NOS).

Authors: Odelya E Pagovich; Katie M Stiles; Anna E Camilleri; Anthony R Russo; Saparja Nag; Ronald G Crystal
Journal: Leukemia Date: 2021-09-20 Impact factor: 11.528

Review 3. Common and Novel Markers for Measuring Inflammation and Oxidative Stress Ex Vivo in Research and Clinical Practice-Which to Use Regarding Disease Outcomes?

Authors: Alain Menzel; Hanen Samouda; Francois Dohet; Suva Loap; Mohammed S Ellulu; Torsten Bohn
Journal: Antioxidants (Basel) Date: 2021-03-09